FDA grants accelerated approval to Vera Therapeutics' Trutakna

Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins ...
Fierce Pharma

FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), ...
MedPage Today on MSN

First-in-class drug approved for IgA nephropathy

It has not been established whether atacicept slows kidney function decline long-term, how ...
Yahoo Finance

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

As per DelveInsight's analysis, the total market size of BAFF- and APRIL-targeted therapies in the 7MM is expected to surge significantly by 2034. BAFF and APRIL-targeted therapies are actively being ...
ESPN

Baff double hopes bomb in Olympic snowboard cross final

Josie Baff has refused to blame her Australian teammate Adam Lambert after his crash cost her the chance to win a landmark second medal in the snowboard cross at the Milan-Cortina Olympics. Only a few ...
Australian Broadcasting Corporation

Josie Baff wins 2026 Winter Olympic gold, a testament to the power of self-belief

Self-belief is a powerful tool for an athlete to have. The assurity that your training has worked, your skills have been honed, your strength has improved and that there is nothing that you have left ...